Research Interests

Maintenance of vascular access for hemodialysis is one of the major challenges in the care of the hemodialysis patient. Access-related problems are among the most frequent reasons for hospitalization in the end-stage renal disease population, and the cost of vascular access placement and repair in the United States exceeds $700 million per year. Our center participates in an NIDDK-funded consortium of investigators, consisting of seven clinical centers and a data-coordinating center to undertake interventional clinical trials to improve outcomes in patients with fistulas and grafts. Two randomized placebo controlled clinical trials have been designed and are planned to begin recruitment in late 2002. Two clinical trials are currently active. The first trial evaluates the effects of the anti-platelet agent, clopidogrel on prevention of early fistula failure. A second trial studies the effects of Aggrenox™ in the prevention of vascular graft stenosis and thrombosis in hemodialysis patients.

Selected Publications

Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR; American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2002;1 Suppl 2:1-95.

Vazquez MA, Jeyarajah DR, Kielar ML, Lu CY. Long-term outcomes of renal transplantation: a result of the original endowment of the donor kidney and the inflammatory response to both alloantigens and injury. Curr Opin Nephrol Hypertens. 2000 Nov;9(6):643-8.

Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000 Oct;11 Suppl 15:S1-86.

Burkey SH, Vazquez MA, Valentine RJ. De novo renal artery aneurysm presenting 6 years after transplantation: a complication of recurrent arterial stenosis? J Vasc Surg. 2000 Aug;32(2):388-91.

Vazquez MA. Chronic rejection of renal transplants: new clinical insights. Am J Med Sci. 2000 Jul;320(1):43-58.

Lu CY, Penfield JG, Kielar ML, Vazquez MA, Jeyarajah DR. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int. 1999 Jun;55(6):2157-68.

Lu CY, Penfield JG, Khair-el-Din TA, Sicher SC, Kielar ML, Vazquez MA, Che L. Docosahexaenoic acid, a constituent of fetal and neonatal serum, inhibits nitric oxide production by murine macrophages stimulated by IFN gamma plus LPS, or by IFN gamma plus Listeria monocytogenes. J Reprod Immunol. 1998 Apr;38(1):31-53.